De Novo device
TrueTear Intranasal Tear Neurostimulator
Allergan · Intranasal Electrostimulation Device For Dry Eye Symptoms (QBR, Class II) · First FDA decision May 17, 2018, newest Aug 31, 2020Dry eye
Last checked: Nov 19, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
2
De Novo pathway
Device trials
9
Naming "TrueTear"
MAUDE reports
0
Brand "TrueTear", since 2015
PubMed studies
3
Mentioning "TrueTear"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing TrueTear Intranasal Tear Neurostimulator
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 2 of 2 decisions filed under this name.
K193589 · Decided Aug 31, 2020 · 252 days after receipt
Device type: Intranasal Electrostimulation Device For Dry Eye Symptoms (QBR) · Ophthalmology
- TrueTear Intranasal Tear NeurostimulatorNew device typeDe Novo
DEN170086 · Decided May 17, 2018 · 206 days after receipt
Device type: Intranasal Electrostimulation Device For Dry Eye Symptoms (QBR) · Ophthalmology
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
No Medicare coverage document has a title matching this device or device type. Many devices are paid under existing codes without one.
Clinical trials
Device studies on ClinicalTrials.gov that name "TrueTear", any status and sponsor, newest update first.
Tufts Medical CenterAcademic, hospital or other
NCT03674892 · 21 participants · Start Sep 28, 2018 · Primary completion Sep 9, 2022
Device: TrueTear™ intranasal neurostimulator (ITN) · For: Cornea
Sites: Boston, Massachusetts
University of PennsylvaniaAcademic, hospital or other
NCT03719885 · 55 participants · Start Dec 1, 2018 · Primary completion Apr 25, 2019
Device: TrueTear Intranasal Tear Neurostimulator · For: Dry Eye Syndromes; Sjogren's Syndrome
Sites: Philadelphia, Pennsylvania
- Intranasal Neurostimulation for the Treatment of Neurosensory Abnormalities in CL Wearers (INTAC)Withdrawn
Tufts Medical CenterAcademic, hospital or other
NCT04240587 · 0 participants · Start Mar 23, 2020 · Primary completion Nov 3, 2021
Device: TrueTear™ intranasal neurostimulator (ITN) · For: Contact Allergy; Neuropathic Pain
Sites: Boston, Massachusetts
6 more trials with a free account
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "TrueTear", and for the whole product code for context.
This brand
0 reports: 0 malfunction, 0 injury, 0 death
Whole product code QBR
0 reports: 0 malfunction, 0 injury, 0 death
Newest reports for this brand
No MAUDE reports name this brand.
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "TrueTear"[tiab]. The summary above synthesizes these.
- Effect of non-invasive intranasal neurostimulation on tear volume, dryness and ocular pain.
Farhangi M, Cheng AM, Baksh B, et al. · Br J Ophthalmol · 2020Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't
- Infrared meibography allows detection of dimensional changes in meibomian glands following intranasal neurostimulation.
Pondelis N, Dieckmann GM, Jamali A, et al. · Ocul Surf · 2020Research Support, Non-U.S. Gov't
- [Research progress on neuromodulation therapy for dry eye].
Li YT, Zeng QY · Zhonghua Yan Ke Za Zhi · 2025Review, English Abstract
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.